High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab
Abstract Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended in international guidelines. In thes...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley
2021-12-01
|
| Edice: | Clinical and Translational Allergy |
| Témata: | |
| On-line přístup: | https://doi.org/10.1002/clt2.12085 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
